Based on this evidence, a single phase 2 non-comparative non-randomized single center study of azacitidine in adults with recurrent IDH-mutant glioma is in the planning stages (ClinicalTrials.gov NCT03666559). This evidence concerns the gene IDH1 and central nervous system cancer.